A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons

Neurotoxicity Research

Volumn 18, Issue 2, 2010, Pages 187-199

  Orio, Laura ^a   Llopis, Noemi ^a   Torres, Elisa ^a   Izco, Maria ^a   O'Shea, Esther ^a   Colado, M Isabel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

3,4 Methylenedioxymethamphetamine; Interleukin 1 ; Microglia; Minocycline; Neurotoxicity; Nuclear factor kappaB

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MINOCYCLINE; NEUROPROTECTIVE AGENT; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL; ARTICLE; DRUG ADMINISTRATION; DRUG EFFECT; FEVER; FRONTAL LOBE; HYPOTHALAMUS; IMMUNOLOGY; INFLAMMATION; MALE; METABOLISM; METHODOLOGY; MICROGLIA; NERVE CELL; PATHOLOGY; RADIOASSAY; RAT; RAT STRAIN; TOXICITY AND INTOXICATION;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; FEVER; FRONTAL LOBE; HYPOTHALAMUS; INFLAMMATION; INTERLEUKIN-1BETA; MALE; MICROGLIA; MINOCYCLINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; NF-KAPPA B; PAROXETINE; RADIOLIGAND ASSAY; RATS; RATS, INBRED STRAINS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 77956656190     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-009-9120-3     Document Type: Article

References (58)

1. Ahn KS, Aggarwal BB (2005) Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci 1056:218-233
2. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB (1996) A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci 93:14014-14019
3. Auron PE (1998) The interleukin 1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev 9:221-237
4. Baldwin AS Jr (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann Rev Immunol 14:649-683
5. Bowie A, O'Neill LA (2000) Oxidative stress and nuclear factorkappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59:13-23
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
7. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801
8. Colado MI, O'Shea E, Granados R, Murray TK, Green AR (1997) In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 121:889-900
9. Colado MI, Esteban B, O'Shea E, Granados R, Green AR (1999) Studies on the neuroprotective effect of pentobarbitone on MDMA-induced neurodegeneration. Psychopharmacology 142:421-425
10. Díaz-Guerra MJ, Velasco M, Martín-Sanz P, Bosca L (1996) Evidence for common mechanisms in the transcriptional control of type II nitric oxide synthase in isolated hepatocytes. Requirement of NF-kappaB activation after stimulation with bacterial cell wall products and phorbol esters. J Biol Chem 271:30114-30120
11. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98:14669-14674
12. Esteban B, O'Shea E, Camarero J, Sanchez V, Green AR, Colado MI (2001) 3, 4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology (Berl) 154:251-260
13. Ferrari D, Villalba M, Chiozzi P, Falzoni S, Ricciardi-Castagnoli P, Di Virgilio F (1996) Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J Immunol 156:1531-1539
14. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):S81-S96
15. Ghosh S, May MJ, Kopp EB (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260
16. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508
17. Griffin BD, Moynagh PN (2006) Persistent interleukin-1beta signaling causes long term activation of NFkappaB in a promoter-specific manner in human glial cells. J Biol Chem 281:10316-10326
18. Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M, Kikugawa K (2003) Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J 22:3356-3366
19. He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909:187-193
20. Hewitt KE, Green AR (1994) Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('ecstasy') to rats. Neuropharmacology 33:1589-1595
21. Hu X, Nesic-Taylor O, Qiu J, Rea HC, Fabian R, Rassin DK, Perez-Polo JR (2005) Activation of nuclear factor-kappaB signaling pathway by interleukin-1 after hypoxia/ischemia in neonatal rat hippocampus and cortex. J Neurochem 93:26-37
22. Imam SZ, Newport GD, Itzhak Y, Cadet JL, Islam F Jr, Slikker W, Ali SF (2001) Peroxynitrite plays a role in methamphetamineinduced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J Neurochem 76:745-749
23. Jensen KF, Olin J, Haykal-Coates N, O'Callaghan J, Miller DB, De Olmos JS (1993) Mapping toxicant-induced nervous system damage with a cupric silver stain: a quantitative analysis of neural degeneration induced by 3, 4-methylenedioxymethamphetamine. NIDA Res Monogr 136:133-149
24. Konsman JP, Tridon V, Dantzer R (2000) Diffusion and action of intracerebroventricularly injected interleukin-1 in the CNS. Neuroscience 101:957-967
25. Lai YT, Tsai YP, Cherng CG, Ke JJ, Ho MC, Tsai CW, Yu L (2009) Lipopolysaccharide mitigates methamphetamine-induced striatal dopamine depletion via modulating local TNF-alpha and dopamine transporter expression. J Neural Transm 116:405-415
26. Lindberg C, Eriksson C, Van Dam AM, Winblad B, Schultzberg M (2004) Neuronal expression of caspase-1 immunoreactivity in the rat central nervous system. J Neuroimmunol 146:99-113
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
28. March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V, Gillis S, Henney CS, Kronheim SR, Grabstein K et al (1985) Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 315:641-647
29. Mattson MP, Camandola S (2001) NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 107:247-254
30. Mievis S, Levivier M, Communi D, Vassart G, Brotchi J, Ledent C, Blum D (2007) Lack of minocycline efficiency in genetic models of Huntington's disease. Neuromolecular Med 9:47-54
31. Miossec C, Decoen MC, Durand L, Fassy F, Diu-Hercend A (1996) Use of monoclonal antibodies to study interleukin-1 beta-converting enzyme expression: only precursor forms are detected in interleukin-1 beta-secreting cells. Eur J Immunol 26:1032-1042
32. Mohr S (2004) Potential new strategies to prevent the development of diabetic retinopathy. Expert Opin Investig Drugs 13:189-198
33. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann N Y Acad Sci 600:649-661
34. Nadjar A, Tridon V, May MJ, Ghosh S, Dantzer R, Amédée T, Parnet P (2005) NFkappaB activates in vivo the synthesis of inducible Cox-2 in the brain. J Cereb Blood Flow Metab 25:1047-1059
35. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8:2788-2803
36. O'Shea E, Granados R, Esteban B, Colado MI, Green AR (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37:919-926
37. O'Shea E, Sanchez V, Orio L, Escobedo I, Green AR, Colado MI (2005) 3, 4-Methylenedioxymethamphetamine increases prointerleukin-1beta production and caspase-1 protease activity in frontal cortex, but not in hypothalamus, of Dark Agouti rats: role of interleukin-1beta in neurotoxicity. Neuroscience 135:1095-1105
38. O'Shea E, Orio L, Escobedo I, Sanchez V, Camarero J, Green AR, Colado MI (2006) MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature. Br J Pharmacol 148:778-785
39. Orio L, O'Shea E, Sanchez V, Pradillo JM, Escobedo I, Camarero J, Moro MA, Green AR, Colado MI (2004) 3, 4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem 89:1445-1453
40. Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866
41. Rifkin BR, Vernillo AT, Golub LM (1993) Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemicallymodified analogs. J Periodontol 64:819-827
42. Ryu JK, Franciosi S, Sattayaprasert P, Kim SU, McLarnon JG (2004) Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia 48:85-90
43. Sanchez V, Camarero J, Esteban B, Peter MJ, Green AR, Colado MI (2001) The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Br J Pharmacol 134:46-57
44. Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI, Green AR (2004) Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurons. J Psychopharmacol. 18:412-416
45. Shankaran M, Yamamoto BK, Gudelsky GA (1999) Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3, 4-methylenedioxymethamphetamine. Eur J Pharmacol 385:103-110
46. Singer II, Scott S, Chin J, Bayne EK, Limjuco G, Weidner J, Miller DK, Chapman K, Kostura MJ (1995) The interleukin-1 betaconverting enzyme (ICE) is localized on the external cell surface membranes and in the cytoplasmic ground substance of human monocytes by immuno-electron microscopy. J Exp Med 182:1447-1459
47. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, Ramer MS, Tetzlaff W (2004) Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 24:2182-2190
48. Stone DM, Merchant KM, Hanson GR, Gibb JW (1987) Immediate and long-term effects of 3, 4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26:1677-1683
49. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J et al (1992) A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356:768-774
50. Tikka TM, Koistinaho JE (2001) Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 166:7527-7533
51. Tringali G, Mancuso C, Mirtella A, Pozzoli G, Parente L, Preziosi P, Navarra P (1996) Evidence for the neuronal origin of immunoreactive interleukin-1 beta released by rat hypothalamic explants. Neurosci Lett 219:143-146
52. Tringali G, Mirtella A, Mancuso C, Guerriero G, Preziosi P, Navarra P (1997) The release of immunoreactive interleukin-1 beta from rat hypothalamic explants is modulated by neurotransmitters and corticotropin-releasing hormone. Pharmacol Res 36:269-273
53. Tsuchihashi S, Tamaki T, Tanaka M, Kawamura A, Kaizu T, Ikeda A, Kakita A (2003) Pyrrolidine dithiocarbamate provides protection against hypothermic preservation and transplantation injury in the rat liver: the role of heme oxygenase-1. Surgery 133:556-567
54. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763-1771
55. Xie QW, Kashiwabara Y, Nathan C (1994) Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 269:4705-4708
56. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J (1998) Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 95:15769-15774
57. Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96:13496-13500
58. Zhang L, Shirayama Y, Shimizu E, Iyo M, Hashimoto K (2006) Protective effects of minocycline on 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur J Pharmacol 544:1-9